Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the quarter ended March 31, 2001. Gilead is an independent biopharmaceutical company focused on infectious diseases and cancer. Key products include AmBisome (antifungal), DaunoXome (Kaposi's Sarcoma), and VISTIDE (CMV retinitis). The company also co-develops Tamiflu with Roche. All share and per-share data reflect a two-for-one stock split completed on February 22, 2001.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenues | $57.8 million | $47.7 million |
| Net Loss | $(21.7) million | $(16.9) million |
| Loss per Share (Diluted) | $(0.23) | $(0.19) |
| Operating Cash Flow | $(30.2) million | $(5.6) million |
| Cash & Marketable Securities | $483.8 million | $291.8 million |
| Convertible Notes Outstanding | $250.0 million | $79.5 million (converted) |
| Accumulated Deficit | $(527.7) million | Not reported |
Revenue Breakdown: Product sales were $45.1 million (93% from AmBisome), royalty revenue was $6.2 million, and contract revenue was $6.4 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 21% year-over-year, driven by a 21% increase in AmBisome sales and higher contract revenue.
- R&D Spike: Research and development expenses surged 95% to $51.1 million. This was primarily due to a $10.6 million upfront license fee for daptomycin (Cubist agreement) and increased Phase III clinical costs for tenofovir DF and adefovir dipivoxil.
- Royalty Decline: Royalty revenue dropped 23% to $6.2 million, largely due to a lighter 2000-2001 flu season reducing Tamiflu royalties from Roche.
- Accounting Change: Adoption of SFAS 133 (Derivatives) resulted in a $1.1 million cumulative credit to operations, partially offsetting the net loss.
- Interest Expense: Interest expense more than doubled to $3.5 million due to the issuance of $250 million in 5% convertible subordinated notes in December 2000.
Outlook, Risks, and Management Commentary
- Guidance: Management expects full-year 2001 R&D expenses to be 20-30% higher than 2000 levels, and SG&A expenses to be 25-40% higher, driven by commercialization preparations for tenofovir DF.
- Liquidity: The company holds $483.8 million in cash and marketable securities. Management believes existing resources are adequate for the foreseeable future but may require additional funding via equity, debt, or collaborations.
- Key Risks:
- AmBisome Dependence: Significant reliance on AmBisome sales, which face competition from lower-priced and newly approved products.
- Regulatory Uncertainty: Risks regarding FDA/EMA approval for tenofovir DF and other pipeline products.
- Foreign Currency: A significant majority of sales are in foreign currencies; a stronger U.S. dollar negatively impacts reported revenue.
- Collaboration Risks: Dependence on partners like Roche and Fujisawa for commercialization and milestone payments.
- Recent Developments: In May 2001, Gilead submitted a New Drug Application (NDA) for tenofovir DF to the FDA and EMA.
Investor Verification Checklist
- Verify the collectibility of $19.5 million in past-due accounts receivable from Greece, Spain, and Italy ($9.2 million is >120 days past due).
- Monitor the regulatory approval timeline and commercial launch strategy for tenofovir DF.
- Assess the impact of the $13.0 million Cubist license fee on future R&D burn rates.
- Track the performance of AmBisome against new competitive entrants in the antifungal market.
- Review the status of milestone payments from Roche (Tamiflu) and EyeTech (NX 1838).